Library — CHDR

Search

Filter

Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.

Guan Z, Klumpers LE, Oyetayo OO, Heuberger J, van Gerven JM, Stevens J

British journal of clinical pharmacology, 2016 Mar; 81(4):713-23

View publication
The use of biomarkers in human pharmacology (Phase I) studies.

Cohen AF, Burggraaf J, van Gerven JM, Moerland M, Groeneveld GJ

Annual review of pharmacology and toxicology, 2015 Apr

View publication
Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.

Szabo ST, Kinon BJ, Brannan SK, Krystal AK, van Gerven JM, Mahableshwarkar A, Sachs GS

Innovations in clinical neuroscience, 2015 Apr; 12(3-4):11S-25S

View publication
Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers.

Kleinloog D, Uit den Boogaard A, Dahan A, Mooren R, Klaassen E, Stevens J, Freijer J, van Gerven J

Journal of psychopharmacology (Oxford, England), 2015 Mar; 29(4):401-13

View publication
Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.

Heuberger JA, Guan Z, Oyetayo OO, Klumpers L, Morrison PD, Beumer TL, van Gerven JM, Cohen AF, Freijer J

Clinical pharmacokinetics, 2015 Jan; 54(2):209-19

View publication
The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol.

Kleinloog D, Stevens J, Heuberger J, Spinhoven P, van Gerven J

Psychiatry research, 2014 Dec; 220(3):945-53

View publication
Profiling the subjective effects of Δ⁹-tetrahydrocannabinol using visual analogue scales.

Kleinloog D, Roozen F, De Winter W, Freijer J, Van Gerven J

International journal of methods in psychiatric research, 2014 May; 23(2):245-56

View publication
Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.

Klumpers LE, Fridberg M, de Kam ML, Little PB, Jensen NO, Kleinloog HD, Elling CE, van Gerven JM

British journal of clinical pharmacology, 2013 Nov; 76(6):846-57

View publication
Pharmacokinetics and pharmacodynamics of orally administered clonidine: a model-based approach.

Klein RH, Alvarez-Jimenez R, Sukhai RN, Oostdijk W, Bakker B, Reeser HM, Ballieux BE, Hu P, Klaassen ES, Freijer J, Burggraaf J, Cohen AF, Wit JM

Hormone research in paediatrics, 2013 Mar; 79(5):300-9

View publication

«
1
2
3
4
5
6
7
»